| CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome F Taube, JA Georgi, M Kramer, S Stasik, JM Middeke, C Röllig, U Krug, ... Blood, The Journal of the American Society of Hematology 139 (1), 87-103, 2022 | 123 | 2022 |
| Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia S Ottema, R Mulet-Lazaro, HB Beverloo, C Erpelinck, S van Herk, ... Blood, The Journal of the American Society of Hematology 136 (2), 224-234, 2020 | 61 | 2020 |
| The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops S Ottema, R Mulet-Lazaro, C Erpelinck-Verschueren, S van Herk, ... Nature Communications 12 (1), 5679, 2021 | 47 | 2021 |
| PopHuman: the human population genomics browser S Casillas, R Mulet, P Villegas-Miron, S Hervas, E Sanz, D Velasco, ... Nucleic acids research 46 (D1), D1003-D1010, 2018 | 44 | 2018 |
| Novel neuroprotective multicomponent therapy for amyotrophic lateral sclerosis designed by networked systems M Herrando-Grabulosa, R Mulet, A Pujol, JM Mas, X Navarro, P Aloy, ... PLoS One 11 (1), e0147626, 2016 | 39 | 2016 |
| Selective requirement of MYB for oncogenic hyperactivation of a translocated enhancer in leukemia L Smeenk, S Ottema, R Mulet-Lazaro, A Ebert, M Havermans, AA Varea, ... Cancer discovery 11 (11), 2868-2883, 2021 | 34 | 2021 |
| Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML R Mulet-Lazaro, S van Herk, C Erpelinck, E Bindels, MA Sanders, ... Blood, The Journal of the American Society of Hematology 138 (2), 160-177, 2021 | 22 | 2021 |
| Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia A Tanaka, TA Nakano, M Nomura, H Yamazaki, JP Bewersdorf, ... Blood, The Journal of the American Society of Hematology 140 (8), 875-888, 2022 | 17 | 2022 |
| Systems biology applied to non-alcoholic fatty liver disease (NAFLD): treatment selection based on the mechanism of action of nutraceuticals S Perera, L Artigas, R Mulet, JM Mas, T Sardón Nutrafoods 13, 61-68, 2014 | 13 | 2014 |
| From Genotype to Phenotype: How Enhancers Control Gene Expression and Cell Identity in Hematopoiesis R Mulet-Lazaro, R Delwel HemaSphere 7 (11), e969, 2023 | 7 | 2023 |
| Induced cell-autonomous neutropenia systemically perturbs hematopoiesis in Cebpa enhancer-null mice R Avellino, R Mulet-Lazaro, M Havermans, R Hoogenboezem, L Smeenk, ... Blood advances 6 (5), 1406-1419, 2022 | 7 | 2022 |
| STAG2 mutations reshape the cohesin-structured spatial chromatin architecture to drive gene regulation in acute myeloid leukemia A Fischer, B Hernández-Rodríguez, R Mulet-Lazaro, M Nuetzel, F Hölzl, ... Cell Reports 43 (8), 2024 | 6 | 2024 |
| Oncogene EVI1 drives acute myeloid leukemia via a targetable interaction with CTBP2 D Pastoors, M Havermans, R Mulet-Lazaro, D Brian, W Noort, J Grasel, ... Science Advances 10 (20), eadk9076, 2024 | 6 | 2024 |
| Cellular and metabolic characteristics of pre-leukemic hematopoietic progenitors with GATA2 haploinsufficiency A Rein, I Geron, E Kugler, H Fishman, E Gottlieb, I Abramovich, A Giladi, ... Haematologica 108 (9), 2316, 2022 | 6 | 2022 |
| Oncogenic enhancers in leukemia R Mulet-Lazaro, R Delwel Blood Cancer Discovery 5 (5), 303-317, 2024 | 3 | 2024 |
| Aberrant DNA methylation patterns in microsatellite stable human colorectal cancers define a new marker panel for the CpG island methylator phenotype C Gebhard, R Mulet-Lazaro, D Glatz, L Schwarzfischer-Pfeilschifter, ... International journal of cancer, 2021 | 3 | 2021 |
| Epigenetic alterations affecting hematopoietic regulatory networks as drivers of mixed myeloid/lymphoid leukemia R Mulet-Lazaro, S van Herk, M Nuetzel, A Sijs-Szabo, N Díaz, K Kelly, ... Nature Communications 15 (1), 5693, 2024 | 2 | 2024 |
| Complex 3q26/EVI1 Rearrangements Genocopy Inv (3)/t (3; 3) Acute Myeloid Leukemias By Enhancer Hijacking, EVI1 Overexpression, Absent MDS1-EVI1 and Low GATA2 Expression S Ottema, R Mulet-Lazaro, B Beverloo, M Havermans, ... Blood 132, 2766, 2018 | 1 | 2018 |
| A Novel XACT lncRNA Transcript with Functions Transcending X-Chromosome Inactivation. P Zhang, PH Angles, H Zhang, T Li, R Mulet-Lazaro, WFJ van IJcken, ... bioRxiv, 2025.01. 03.631201, 2025 | | 2025 |
| MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia D Pastoors, M Havermans, R Mulet-Lazaro, L Smeenk, S Ottema, ... bioRxiv, 2025.01. 02.631046, 2025 | | 2025 |
